Profile of idursulfase for the treatment of Hunter syndrome

References

• Hunter C. A rare disease in two brothers. Proc R Soc Med. 1917;10:104–106.
   Google Scholar
• Bach G, Eisenberg F Jr, Cantz M, Neufeld EF. The defect in the Hunter syndrome: deficiency of sulfoiduronate sulfatase. Proc Natl Acad Sci U S A. 1973;70(7):2134–2138.
   PubMed Web of Science ®Google Scholar
• Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill; 2001:3421–3452.
   Google Scholar
• Beck M, Wijburg FA, Gal A. Clinical utility gene card for: mucopolysaccharidosis type II. Eur J Hum Genet. 2012;20(1):1.
   Web of Science ®Google Scholar
• Tuschl K, Gal A, Paschke E, Kircher S, Bodamer OA. Mucopolysaccharidosis type II in females: case report and review of literature. Pediatr Neurol. 2005;32:270–272.
   PubMed Web of Science ®Google Scholar
• Pinto LL, Vieira TA, Giugliani R, Schwartz IV. Expression of the disease on female carriers of X-linked lysosomal disorders: a brief review. Orphanet J Rare Dis. 2010;5:14.
   PubMed Web of Science ®Google Scholar
• Martin R, Beck M, Eng C, et al. Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome). Pediatrics. 2008;121:e377–e386.
   PubMed Web of Science ®Google Scholar
• Wraith JE, Beck M, Giugliani R, Clarke J, Martin R, Muenzer J. Initial report from the Hunter outcome survey. Genet Med. 2008;10:508–516.
   PubMed Web of Science ®Google Scholar
• Schwartz IV, Ribeiro MG, Mota JG, et al. A clinical study of 77 patients with mucopolysaccharidosis type II. Acta Paediatr Suppl. 2007;96(455):63–70.
   Google Scholar
• Wraith JE, Scarpa M, Beck M, et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr. 2008;167:267–277.
   PubMed Web of Science ®Google Scholar
• Jones SA, Almássy Z, Beck M, et al; HOS Investigators. Mortality and cause of death in mucopolysaccharidosis type II – a historical review based on data from the Hunter outcome survey (HOS). J Inherit Metab Dis. 2009;32:534–543.
   PubMed Web of Science ®Google Scholar
• Vellodi A, Young E, Cooper A, Lidchi V, Winchester B, Wraith JE. Long-term follow-up following bone marrow transplantation for Hunter disease. J Inherit Metab Dis. 1999;22(5):638–648.
   PubMed Web of Science ®Google Scholar
• Guffon N, Bertrand Y, Forest I, Fouilhoux A, Froissart R. Bone marrow transplantation in children with Hunter syndrome: outcome after 7 to 17 years. J Pediatr. 2009;154(5):733–737.
   PubMed Web of Science ®Google Scholar
• Muenzer J, Gucsavas-Calikoglu M, McCandless SE, Schuetz TJ, Kimura A. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Mol Genet Metab. 2007;90(3):329–337.
   PubMed Web of Science ®Google Scholar
• Elaprase® (idursulfase) Solution for Intravenous Infusion [Prescribing Information] Shire Human Genetic Therapies; 2011.
   Google Scholar
• Sohn YB, Cho SY, Park SW, et al. Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter syndrome). Orphanet J Rare Dis. 2013;18(8):42.
   Google Scholar
• Chung YK, Sohn YB, Sohn JM, et al. A biochemical and physicochemical comparison of two recombinant enzymes used for enzyme replacement therapies of Hunter syndrome. Glycoconj J. 2014;31(4):309–315.
   Web of Science ®Google Scholar
• Sohn YB, Cho SY, Lee J, Kwun Y, Huh R, Jin DK. Safety and efficacy of enzyme replacement therapy with idursulfase beta in children aged younger than 6 years with Hunter syndrome. Mol Genet Metab. 2015;114(2):156–160.
   PubMed Web of Science ®Google Scholar
• Muenzer J, Wraith JE, Beck M, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med. 2006;8(8):465–473.
   PubMed Web of Science ®Google Scholar
• Muenzer J, Beck M, Eng CM, et al. Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome. Genet Med. 2011;13(2):95–101.
   PubMed Web of Science ®Google Scholar
• Okuyama T, Tanaka A, Suzuki Y, et al. Japan Elaprase Treatment (JET) Study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (mucopolysaccharidosis II, MPS II). Mol Genet Metab. 2010;99(1):18–25.
   Web of Science ®Google Scholar
• Coppa GV, Buzzega D, Zampini L, et al. Plasmatic and urinary glycosaminoglycans characterization in mucopolysaccharidosis II patient treated with enzyme-replacement therapy with idursulfase. JIMD Rep. 2012;4:79–90.
   Google Scholar
• Glamuzina E, Fettes E, Bainbridge K, et al. Treatment of mucopolysaccharidosis type II (Hunter syndrome) with idursulfase: the relevance of clinical trial end points. J Inherit Metab Dis. 2011;34(3):749–754.
   Web of Science ®Google Scholar
• Alegra T, Eizerik DP, de Cerqueira CC, Pereira TV, Dornelles AD, Schwartz IV. Efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II with and without comparison to placebo: systematic review and meta-analysis. Cad Saude Publica. 2013;29(Suppl 1):S45–S58.
   Google Scholar
• Tchan MC, Devine KT, Sillence DO. Three adult siblings with mucopolysaccharidosis type II (hunter syndrome): a report on clinical heterogeneity and 12 months of therapy with idursulfase. JIMD Rep. 2011;1:57–64.
   Google Scholar
• Westhoff M, Litterst P. Successful noninvasive ventilation and enzyme replacement therapy in an adult patient with morbus hunter. JIMD Rep. 2012;5:77–82.
   Google Scholar
• Schulze-Frenking G, Jones SA, Roberts J, Beck M, Wraith JE. Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II. J Inherit Metab Dis. 2011;34(1):203–208.
   Web of Science ®Google Scholar
• Kuczmarski RJ, Ogden CL, Guo SS, et al. 2000 CDC growth charts for the United States: methods and development. Vital Health Stat. 2002;246:1–190.
   Google Scholar
• Jones SA, Parini R, Harmatz P, et al; HOS Natural History Working Group on behalf of HOS Investigators. The effect of idursulfase on growth in patients with Hunter syndrome: data from the Hunter outcome survey (HOS). Mol Genet Metab. 2013;109(1):41–48.
   Web of Science ®Google Scholar
• Cho SY, Huh R, Chang MS, et al. Impact of enzyme replacement therapy on linear growth in Korean patients with mucopolysaccharidosis type II (Hunter syndrome). J Korean Med Sci. 2014;29(2):254–260.
   Web of Science ®Google Scholar
• Brands MM, Frohn-Mulder IM, Hagemans ML, et al. Mucopolysaccharidosis: cardiologic features and effects of enzyme-replacement therapy in 24 children with MPS I, II and VI. J Inherit Metab Dis. 2013;36(2):227–234.
   Web of Science ®Google Scholar
• Sato Y, Fujiwara M, Kobayashi H, Ida H. Massive accumulation of glycosaminoglycans in the aortic valve of a patient with Hunter syndrome during enzyme replacement therapy. Pediatr Cardiol. 2013;34(8):2077–2079.
   Web of Science ®Google Scholar
• Fesslová V, Corti P, Sersale G, et al. The natural course and the impact of therapies of cardiac involvement in the mucopolysaccharidoses. Cardiol Young. 2009;19(2):170–178.
   Web of Science ®Google Scholar
• Manara R, Priante E, Grimaldi M, et al. Brain and spine MRI features of Hunter disease: frequency, natural evolution and response to therapy. J Inherit Metab Dis. 2011;34(3):763–780.
   Web of Science ®Google Scholar
• Burton BK, Whiteman DA; HOS Investigators. Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: a perspective from the Hunter outcome survey (HOS). Mol Genet Metab. 2011;103(2):113–120.
   PubMed Web of Science ®Google Scholar
• Miebach E. Management of infusion-related reactions to enzyme replacement therapy in a cohort of patients with mucopolysaccharidosis disorders. Int J Clin Pharmacol Ther. 2009;47(Suppl 1):S100–S106.
   Google Scholar
• Serrano CD, Gomez JF. Successful desensitization to idursulfase in a patient with type II mucopolysaccharidosis (Hunter syndrome). J Investig Allergol Clin Immunol. 2011;21(7):571–572.
   Web of Science ®Google Scholar
• Kim J, Park MR, Kim DS, et al. IgE-mediated anaphylaxis and allergic reactions to idursulfase in patients with Hunter syndrome. Allergy. 2013;68(6):796–802.
   Web of Science ®Google Scholar
• Barbier AJ, Bielefeld B, Whiteman DA, Natarajan M, Pano A, Amato DA. The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase. Mol Genet Metab. 2013;110(3):303–310.
   PubMed Web of Science ®Google Scholar
• Scarpa M, Almássy Z, Beck M, et al; Hunter Syndrome European Expert Council. Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease. Orphanet J Rare Dis. 2011;6:72.
   PubMed Web of Science ®Google Scholar
• Burton BK, Wiesman C, Paras A, Kim K, Katz R. Home infusion therapy is safe and enhances compliance in patients with mucopolysaccharidoses. Mol Genet Metab. 2009;97(3):234–236.
   Web of Science ®Google Scholar
• Milligan A, Hughes D, Goodwin S, Richfield L, Mehta A. Intravenous enzyme replacement therapy: better in home or hospital? Br J Nurs. 2006;15(6):330–333.
   Google Scholar
• Hughes DA, Mlilligan A, Mehta A. Home therapy for lysosomal storage disorders. Br J Nurs. 2007;16(22):1386–1389.
   Google Scholar
• Ceravolo F, Mascaro I, Sestito S, et al. Home treatment in paediatric patients with Hunter syndrome: the first Italian experience. Ital J Pediatr. 2013;39:53.
   Web of Science ®Google Scholar
• Bagewadi S, Roberts J, Mercer J, Jones S, Stephenson J, Wraith JE. Home treatment with Elaprase and Naglazyme is safe in patients with mucopolysaccharidoses types II and VI, respectively. J Inherit Metab Dis. 2008;31(6):733–737.
   Web of Science ®Google Scholar
• Alcalde-Martín C, Muro-Tudelilla JM, Cancho-Candela R, et al. First experience of enzyme replacement therapy with idursulfase in Spanish patients with Hunter syndrome under 5 years of age: case observations from the Hunter outcome survey (HOS). Eur J Med Genet. 2010;53(6):371–377.
   PubMed Web of Science ®Google Scholar
• Tomanin R, Zanetti A, D’Avanzo F, et al. Clinical efficacy of enzyme replacement therapy in paediatric Hunter patients, an independent study of 3.5 years. Orphanet J Rare Dis. 2014;9(1):129.
   PubMed Web of Science ®Google Scholar
• Muenzer J, Beck M, Giugliani R, et al. Idursulfase treatment of Hunter syndrome in children younger than 6 years: results from the Hunter outcome survey. Genet Med. 2011;13(2):102–109.
   PubMed Web of Science ®Google Scholar
• Dittrich M, Milde S, Dinkel E, Baumann W, Weitzel D. Sonographic biometry of liver and spleen size in childhood. Pediatr Radiol. 1983;13:206–211.
   PubMed Web of Science ®Google Scholar
• Giugliani R, Hwu WL, Tylki-Szymanska A, Whiteman DA, Pano A. A multicenter, open-label study evaluating safety and clinical outcomes in children (1.4–7.5 years) with Hunter syndrome receiving idursulfase enzyme replacement therapy. Genet Med. 2014;16(6):435–441.
   PubMed Web of Science ®Google Scholar
• Lampe C, Atherton A, Burton BK, et al. Enzyme replacement Therapy in mucopolysaccharidosis II patients under 1 year of age. JIMD Rep. 2014;14:99–113.
   Google Scholar
• Tajima G, Sakura N, Kosuga M, Okuyama T, Kobayashi M. Effects of idursulfase enzyme replacement therapy for mucopolysaccharidosis type II when started in early infancy: comparison in two siblings. Mol Genet Metab. 2013;108:172–177.
   PubMed Web of Science ®Google Scholar
• Tylki-Szymanska A, Jurecka A, Zuber Z, Rozdzynska A, Marucha J, Czartoryska B. Enzyme replacement therapy for mucopolysaccharidosis II from 3 months of age: a 3-year follow-up. Acta Paediatr. 2012;101:e42–e47.
   PubMed Web of Science ®Google Scholar
• Żuber Z, Różdżyńska-Świątkowska A, Jurecka A, Tylki-Szymańska A. The effect of recombinant human iduronate-2-sulfatase (Idursulfase) on growth in young patients with mucopolysaccharidosis type II. PLoS One. 2014;9(1):e85074.
   Web of Science ®Google Scholar
• Muenzer J. Early initiation of enzyme replacement therapy for the mucopolysaccharidoses. Mol Genet Metab. 2014;111(2):63–72.
   PubMed Web of Science ®Google Scholar
• Muenzer J, Bodamer O, Burton B, et al. The role of enzyme replacement therapy in severe Hunter syndrome – an expert panel consensus. Eur J Pediatr. 2012;171(1):181–188.
   PubMed Web of Science ®Google Scholar
• Boado RJ, Hui EK, Lu JZ, Sumbria RK, Pardridge WM. Blood-brain barrier molecular Trojan horse enables imaging of brain uptake of radioiodinated recombinant protein in the rhesus monkey. Bioconjug Chem. 2013;24(10):1741–1749.
   PubMed Web of Science ®Google Scholar
• Lampe C, Bosserhoff AK, Burton BK, et al. Long-term experience with enzyme replacement therapy (ERT) in MPS II patients with a severe phenotype: an international case series. J Inherit Metab Dis. 2014;37(5):823–829.
   PubMed Web of Science ®Google Scholar
• Felice BR, Wright TL, Boyd RB, et al. Safety evaluation of chronic intrathecal administration of idursulfase-IT in cynomolgus monkeys. Toxicol Pathol. 2011;39(5):879–892.
   PubMed Web of Science ®Google Scholar
• Dickson PI. Novel treatments and future perspectives: outcomes of intrathecal drug delivery. Int J Clin Pharmacol Ther. 2009;47(Suppl 1):S124–S127.
   Google Scholar
• Calias P, Papisov M, Pan J, et al. CNS penetration of intrathecal-lumbar idursulfase in the monkey, dog and mouse: implications for neurological outcomes of lysosomal storage disorder. PLoS One. 2012;7(1):e30341.
   PubMed Web of Science ®Google Scholar